Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - CVS HEALTH Corp | dp22504_ex0501.htm |
| EX-4.2 - EXHIBIT 4.2 - CVS HEALTH Corp | dp22504_ex0402.htm |
| EX-4.1 - EXHIBIT 4.1 - CVS HEALTH Corp | dp22504_ex0401.htm |
| EX-1.1 - EXHIBIT 1.1 - CVS HEALTH Corp | dp22504_ex0101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 Or 15(d) of The Securities Exchange Act of 1934
|
Date of report (Date of earliest event reported): May 9, 2011
|
||
|
CVS CAREMARK CORPORATION
|
||
|
(Exact name of registrant
as specified in charter)
|
||
|
Delaware
|
001-01011
|
05-0494040
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
One CVS Drive, Woonsocket, Rhode Island 02895
|
||
|
(Address of principal executive offices)
|
||
|
Registrant’s telephone number, including area code: (401) 765-1500
|
||
|
(Former name or former address, if changed since last report)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On May 9, 2011, CVS Caremark Corporation, a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., J.P. Morgan Securities LLC, BNY Mellon Capital Markets, LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $550,000,000 aggregate principal amount of its 4.125% senior notes due May 15, 2021 ( the “2021 Notes”) and $950,000,000 aggregate principal amount of its 5.750% senior notes due May 15, 2041 (the “2041 Notes” and together with the 2021 Notes, the “Notes”). The Notes were offered pursuant to the Company’s Registration Statement on Form S-3, File No. 333-165672, dated March 24, 2010.
From time to time, certain of the Underwriters and/or their respective affiliates have directly and indirectly engaged, and may engage in the future, in investment and/or commercial banking transactions with the Company for which they have received, or may receive, customary compensation, fees and expense reimbursement.
The closing of the sale of the Notes will occur on May 12, 2011. The net proceeds to the Company from the sale of the Notes, after deducting the Underwriters’ discounts and commissions and the estimated net offering expenses payable by the Company, are approximately $1,463,106,350. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this report on Form 8-K and is incorporated by reference into the Registration Statement.
The Notes will be governed by and issued pursuant to a Senior Indenture dated August 15, 2006 between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Senior Indenture”). The Company may issue additional senior debt securities from time to time pursuant to the Senior Indenture. The form of Senior Indenture was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 15, 2006 and shall be incorporated by reference into this report on Form 8-K. The forms of the Notes are filed as Exhibits 4.1 and 4.2 to this report on Form 8-K and are incorporated by reference into the Registration Statement.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. |
Description
|
|
1.1
|
Underwriting Agreement dated May 9, 2011 between CVS Caremark Corporation and Barclays Capital Inc., J.P. Morgan Securities LLC, BNY Mellon Capital Markets, LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule 1 thereto.
|
|
4.1
|
Form of 2021 Note
|
|
4.2
|
Form of 2041 Note
|
|
5.1
|
Opinion of Davis Polk & Wardwell LLP
|
|
23.1
|
Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CVS CAREMARK CORPORATION
|
||||||
|
Date:
|
May 12, 2011
|
By:
|
/s/ David M. Denton
|
|||
|
Name:
|
David M. Denton
|
|||||
|
Title:
|
Executive Vice President and Chief Financial Officer
|
|||||